Submitted:
09 August 2025
Posted:
11 August 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study design and patient cohort
2.2. Preparation of the samples
2.3. IRMS Procedure
Statistical Analysis
3. Results
3.1. Lymph Node Status (pN) and Neck Dissections
3.2. Multivariate logistic regression analysis of the risk factors of cervical lymph node metastasis
3.3. IRMS measurements of nitrogen 15N and carbon 13C in tumor tissues
3.4. Correlation between IRMS measurements and risk factors of cervical lymph node metastasis
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rozanova, S.; Barkovits, K.; Nikolov, M.; Schmidt, C.; Urlaub, H.; Marcus, K. Quantitative mass spectrometry-based proteomics: an overview. Methods Mol. Biol. 2021, 2228, 85–116. [Google Scholar] [CrossRef] [PubMed]
- Leslie, A.; Teh, E.; Druker, A.; Pinto, D.M. A targeted isotope dilution mass spectrometry assay for osteopontin quantification in plasma of metastatic breast cancer patients. PLoS One 2023, 18, e0281491. [Google Scholar] [CrossRef] [PubMed]
- Andersson, A.; Piper, T.; Ekström, L.; Hirschberg, A.L.; Thevis, M. Usefulness of serum androgen isotope ratio mass spectrometry (IRMS) to detect testosterone supplementation in women. Drug Test. Anal. 2023, 15, 465–469. [Google Scholar] [CrossRef] [PubMed]
- Tea, I.; De Luca, A.; Schiphorst, A.M.; Grand, M.; Barillé-Nion, S.; Mirallié, E.; Drui, D.; Krempf, M.; Hankard, R.; Tcherkez, G. Stable isotope abundance and fractionation in human diseases. Metabolites 2021, 11, 370. [Google Scholar] [CrossRef] [PubMed]
- Cichoń, M.J.; Gąsior, K.J.; Hincz, A.; Taran, K. The first pyrolysis protocol based on experimental measurements in the atomic level structured cancer studies. J. Health Study Med. 2022, 1, 5–18. [Google Scholar] [CrossRef]
- Taran, K.; Frączek, T.; Sikora-Szubert, A.; Sitkiewicz, A.; Młynarski, W.; Kobos, J. The first investigation of Wilms’ tumor atomic structure-nitrogen and carbon isotopic composition as a novel biomarker. Oncotarget 2016, 7, 76726–76734. [Google Scholar] [CrossRef] [PubMed]
- Tea, I.; Martineau, E.; Antheaume, I.; Domanski, D.; Tcherkez, G. 13C and 15N natural isotope abundance reflects breast cancer cell metabolism. Sci. Rep, 2016, 6, 34251. [Google Scholar] [CrossRef] [PubMed]
- Phan, L.M.; Yeung, S.C.; Lee, M.H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med. 2014, 11, 1–19. [Google Scholar] [CrossRef] [PubMed]
- Miranda-Gonçalves, V.; Lameirinhas, A.; Henrique, R.; Jerónimo, C. Metabolism and epigenetic interplay in cancer: regulation and putative therapeutic targets. Front. Genet. 2018, 9, 427. [Google Scholar] [CrossRef] [PubMed]
- Faubert, B.; Solmonson, A.; DeBerardinis, R.J. Metabolic reprogramming and cancer progression. Science 2020, 368, eaaw5473. [Google Scholar] [CrossRef] [PubMed]
- Madej, A.; Forma, E.; Golberg, M.; Kamiński, R.; Paneth, P.; Kobos, J.; Różański, W.; Lipiński, M. 13C natural isotope abundance in urothelium as a new marker in the follow-up of patients with bladder cancer. Cancers 2022, 14, 2423. [Google Scholar] [CrossRef] [PubMed]
- Haidari, S.; Obermeier, K.T.; Kraus, M.; Otto, S.; Probst, F.A.; Liokatis, P. Nodal disease and survival in oral cancer: is occult metastasis a burden factor compared to preoperatively nodal positive neck? Cancers 2022, 14, 4241. [Google Scholar] [CrossRef] [PubMed]
- Dammann, F.; Horger, M.; Mueller-Berg, M.; Schlemmer, H.; Claussen, C.; Hoffman, J.; Eschmann, S.; Bares, R. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI and 18 FDG PET. AJR Am. J. Roentgenol. 2005, 184, 1326–1331. [Google Scholar] [CrossRef] [PubMed]
- He, T.; Sun, J.; Wu, J.; Wang, H.; Li, S.; Su, S. PET-CT versus MRI in the diagnosis of lymph node metastasis of cervical cancer: a meta-analysis. Microsc. Res. Tech. 2022, 85, 1791–1798. [Google Scholar] [CrossRef] [PubMed]
- Mashberg, A.; Samit, A. Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. CA Cancer J. Clin. 1995, 45, 328–351. [Google Scholar] [CrossRef] [PubMed]
- Goekerm, M.; Braun, J.; Stoeckli, S.J. Evaluation of clinical and histomorphological parameters as potential predictors of occult metastases in sentinel lymph nodes of early squamous cell carcinoma of the oral cavity. Ann. Surg. Oncol. 2010, 17, 527–535. [Google Scholar]
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers. Version 4.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437 (accessed on 31.07.2025).
- Amin, M.B.; Edge, S.B.; Greene, F.L.; Byrd, D.R.; Brookland, R.K.; Washington, M.K.; Gershenwald, J.E.; Compton, C.C.; Hess, K.R.; Sullivan, D.C.; Jessup, J.M.; Brierley, J.D.; Gaspar, L.E.; Schilsky, R.L.; Balch, C.M.; Winchester, D.P.; Asare, E.A.; Madera, M.; Gress, D.M.; Meyer, L.R.; AJCC cancer staging manual. 8th ed. New York (NY): Springer; 2017. Available online: https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx (accessed on 31.07.2025).
- Bogusiak, K.; Puch, A.; Mostowski, R.; Kozakiewicz, M.; Paneth, P.; Kobos, J. Characteristic of oral squamous cell carcinoma tissues using isotope ratio mass spectrometry. Cancers 2020, 12, 3760. [Google Scholar] [CrossRef] [PubMed]
- Bogusiak, K.; Kozakiewicz, M.; Puch, A.; Mostowski, R.; Paneth, P.; Kobos, J. Oral Cavity Cancer Tissues Differ in Isotopic Composition Depending on Location and Staging. Cancers 2023, 15, 4610. [Google Scholar] [CrossRef] [PubMed]


| Characteristics | Number of patients | ||
| n | % | ||
| Gender | |||
| Male | 37 | 60.7 | |
| Female | 24 | 39.3 | |
| Age | |||
| <65 years | 23 | 37.7 | |
| ≥65 years | 38 | 62.3 | |
| Smoking | |||
| yes | 37 | 60.7 | |
| no | 24 | 39.3 | |
| Alcohol consumption | |||
| yes | 17 | 27.9 | |
| no | 44 | 72.1 | |
| pT stage | |||
| T1 | 2 | 3.3 | |
| T2 | 12 | 19.7 | |
| T3 | 19 | 31.1 | |
| T4 | 28 | 45.9 | |
| Cervical lymph node metastasis | |||
| N0 | 27 | 44.2 | |
| N1 | 2 | 3.3 | |
| N2 | 4 | 6.6 | |
| N3 | 28 | 45.9 | |
| Grading | |||
| G1 | 11 | 18.0 | |
| G2 | 40 | 65.6 | |
| G3 | 10 | 16.4 | |
| AJCC stage | |||
| I | 2 | 3.3 | |
| II | 4 | 6.6 | |
| III | 8 | 13.1 | |
| IV | 47 | 77.0 | |
| Mean | Median | SD | Min | Max | |
| Lymph node yield | 36.9 | 36 | 10.5 | 21 | 59 |
| Number of positive lymph nodes | 3.7 | 3 | 2.4 | 1 | 9 |
| Lymph node ratio | 0.10690 | 0.09090 | 0.07334 | 0.02222 | 0.36 |
| Characteristics | Number of patients | Lymph node metastasis |
χ2 value |
P value | ||
| n | Yes | No | ||||
| Gender | 4.390 | p < 0.05 | ||||
| Male | 37 | 24 | 13 | |||
| Female | 24 | 9 | 15 | |||
| Age | 5.838 | p < 0.05 | ||||
| <65 years | 23 | 17 | 6 | |||
| ≥65 years | 38 | 16 | 22 | |||
| Smoking | 4.390 | p < 0.05 | ||||
| yes | 37 | 24 | 13 | |||
| no | 24 | 9 | 15 | |||
| Alcohol consumption | 1.068 | p > 0.05 | ||||
| yes | 17 | 11 | 6 | |||
| no | 44 | 22 | 22 | |||
| Primary tumor site** | 49.969** | p < 0.05 | ||||
| Buccal Mucosa | 4 | 1 | 3 | |||
| Floor of the mouth | 18 | 11 | 7 | |||
| Lower lip | 4 | 0 | 4 | |||
| Lower gingiva | 18 | 12 | 6 | |||
| Upper gingiva | 8 | 4 | 4 | |||
| Tongue | 9 | 5 | 4 | |||
| Ulceration | 0.236 | p > 0.05 | ||||
| yes | 35 | 18 | 17 | |||
| no | 26 | 15 | 11 | |||
| pT stage | 0.100 | p > 0.05 | ||||
| T1+T2 | 14 | 8 | 6 | |||
| T3 | 19 | 11 | 8 | |||
| T4 | 28 | 14 | 14 | |||
| Depth of infiltration | 4.573 | p < 0.05 | ||||
| ≤ 10 mm* | 28 | 11 | 17 | |||
| > 10 mm | 33 | 22 | 11 | |||
| Stage (AJCC 8th edition) | 22.881 | p < 0.05 | ||||
| I+II+III | 14 | 0 | 14 | |||
| IV | 47 | 33 | 14 | |||
| Angioinvasion and/or Neuroinvasion | 6.573 | p < 0.05 | ||||
| yes | 26 | 19 | 7 | |||
| no | 35 | 14 | 21 | |||
| ENE | N/A | N/A | ||||
| yes | 27 | 27 | 0 | |||
| no | 34 | 6 | 28 | |||
| Keratodes | 6.416 | p < 0.05 | ||||
| yes | 53 | 32 | 21 | |||
| no | 8 | 1 | 7 | |||
| Grade** | 39.165 | p < 0.05 | ||||
| G1 | 11 | 4 | 7 | |||
| G2 | 40 | 24 | 16 | |||
| G3 | 10 | 5 | 5 | |||
| Variables | B value | S.E. value | Wald X2 value | OR (95% ei) | P value | |
| Age | 0.869 | 0.056 | 8.898 | 0.869 (0.779 – 0.970) | 0.0029 | |
| Gender | 0.220 | 0.770 | 4.133 | 0.22 (0.049 – 0.997) | 0.0420 | |
| Tumor stage | ||||||
| I | 2.236 | 223.609 | 34.396 | 2.236 (1.030 – 4.854) | 0.0000 | |
| II | 1.379 | 158.117 | 1.379 (3.546 – 5.364) | |||
| III | 2.896 | 111.805 | 2.896 (1.865 – 4.263) | |||
| Lymph node metastasis | Lymph node metastasis | χ2 value | P value | ||
| Yes | No | ||||
| Nitrogen (%) | Min-Max | 3.10 – 13.40 | 6.40 – 13.10 | 0.195 | 0.097488 |
| Median | 12.70 | 12.50 | |||
| IQR | 0.60 | 0.80 | |||
|
Carbon (%) |
Min-Max | 44.00 – 69.50 | 44.10 – 63.90 | 0.103 | 0.890641 |
| Median | 46.20 | 46.20 | |||
| IQR | 1.40 | 2.00 | |||
| [N]/[C] | Min-Max | 0.045 – 0.316 | 0.104 – 0.291 | 0.641 | 0.195206 |
| Median | 0.274 | 0.272 | |||
| IQR | 0.014 | 0.024 | |||
| δ15N(‰) | Min-Max | 7.240 – 10.218 | 7.500 – 10.838 | 0.064 | 0.249896 |
| Median | 8.800 | 8.700 | |||
| IQR | 1.117 | 0.945 | |||
| δ13C(‰) | Min-Max | -26.506 – -20.072 | -25.780 – -20.858 | 0.103 | 0.116341 |
| Median | -22.304 | -22.746 | |||
| IQR | 1.145 | 0.653 | |||
| Category | Nitrogen (%) | Carbon (%) | |||||||||
| Min-Max | Median | IQR | χ2 | P value | Min-Max | Median | IQR | χ2 | P value | ||
| Age | |||||||||||
| <65 years | 3.10–13.30 | 12.0 | 2.10 | 0.15 | p>0.05 | 44.0–69.50 | 46.0 | 14.40 | 0.02 | p>0.05 | |
| ≥65 years | 3.10–13.10 | 13.0 | 0.70 | 44.0–69.50 | 46.0 | 1.40 | |||||
| Gender | |||||||||||
| Male | 6.30–13.40 | 13.0 | 0.90 | 0.01 | p>0.05 | 44.0–63.90 | 46.0 | 2.60 | 0.04 | p>0.05 | |
| Female | 3.10–13.0 | 13.0 | 0.90 | 44.0–69.50 | 46.0 | 2.10 | |||||
| Stage | |||||||||||
| I+II+III | 6.40–13.40 | 12.0 | 6.10 | 4.12 | p<0.05 | 44.80–63.90 | 46.0 | 15.70 | 0.09 | p>0.05 | |
| IV | 3.10–13.40 | 13.0 | 0.90 | 44.0–69.50 | 46.0 | 1.70 | |||||
| Smoking | |||||||||||
| Yes | 3.10–13.40 | 13.0 | 0.90 | 0.03 | p>0.05 | 44.0–69.50 | 46.0 | 2.00 | 0.06 | p>0.05 | |
| No | 3.10–13.40 | 13.0 | 1.40 | 44.0–69.50 | 46.0 | 5.30 | |||||
| DoI (mm) | |||||||||||
| ≤ 10 mm | 6.50–13.20 | 13.0 | 1.00 | 0.05 | p>0.05 | 44.0–63.90 | 46.0 | 5.40 | 0.08 | p>0.05 | |
| > 10 mm | 3.10–13.40 | 13.0 | 0.80 | 44.0–69.50 | 46.0 | 1.60 | |||||
| Angioinvasion or Neuroinvasion | |||||||||||
| Yes | 3.10–13.0 | 12.0 | 0.70 | 0.07 | p>0.05 | 44.0–69.50 | 46.0 | 1.60 | 0.03 | p>0.05 | |
| No | 5.50–13.40 | 13.0 | 1.40 | 44.0–69.50 | 46.0 | 3.60 | |||||
| ENE(+) (ipsilateral or contralateral) | |||||||||||
| Yes | 10.30–13.40 | 13.0 | 0.90 | 0.09 | p>0.05 | 44.0–50.80 | 46.0 | 1.40 | 0.12 | p>0.05 | |
| No | 3.10–13.40 | 12.0 | 1.10 | 44.0–69.50 | 46.0 | 3.60 | |||||
| Keratodes | |||||||||||
| Yes | 3.10–13.40 | 13.0 | 0.90 | 0.04 | p>0.05 | 44.0–69.50 | 46.0 | 1.60 | 0.05 | p>0.05 | |
| No | 6.60–13.40 | 12.0 | 5.20 | 45.80–63.70 | 46.0 | 13.70 | |||||
| Grade | |||||||||||
| G1 | 6.40–13.10 | 13.0 | 6.20 | 0.06 | p>0.05 | 45.40–63.90 | 46.0 | 15.70 | 0.08 | p>0.05 | |
| G2 | 3.10–13.40 | 13.0 | 0.90 | 44.0–69.50 | 46.0 | 1.70 | |||||
| G3 | 3.10–12.70 | 12.0 | 9.40 | 45.80–69.50 | 46.0 | 23.70 | |||||
| Category | [N]/[C] | δ15N(‰) | δ13C(‰) | |||||||||||||
| Min-Max | Median | IQR | χ2 | P value | Min-Max | Median | IQR | χ2 | P value | Min-Max | Median | IQR | χ2 | P value | ||
| Age | ||||||||||||||||
| <65 years | 0.045–0.316 | 0.27 | 0.066 | 0.08 | p>0.05 | 7.24–10.25 | 8.99 | 1.19 | 0.73 | p>0.05 | -26.51– -20.07 | -22.70 | 2.48 | 0.26 | p>0.05 | |
| ≥65 years | 0.045–0.286 | 0.27 | 0.009 | 7.74–10.84 | 8.65 | 1.34 | -26.51– -20.86 | -22.41 | 1.04 | |||||||
| Gender | ||||||||||||||||
| Male | 0.104–0.316 | 0.27 | 0.034 | 0.02 | p>0.05 | 7.24–10.25 | 8.65 | 1.01 | 0.12 | p>0.05 | -24.69– -20.07 | -22.44 | 1.52 | 0.03 | p>0.05 | |
| Female | 0.045–0.291 | 0.27 | 0.010 | 8.19–10.22 | 8.83 | 1.31 | -26.51– -21.29 | -22.48 | 0.76 | |||||||
| Stage | ||||||||||||||||
| I+II+III | 0.104–0.291 | 0.27 | 0.168 | 0.07 | p>0.05 | 8.13–10.84 | 8.83±0.87 | 1.02 | 0.11 | p>0.05 | -24.68– -22.01 | -22.88 | 1.68 | 4.25 | p<0.05 | |
| IV | 0.045–0.316 | 0.27 | 0.013 | 7.24–10.22 | 8.86±0.67 | 1.35 | -26.51– -20.07 | -22.40 | 2.48 | |||||||
| Smoking | ||||||||||||||||
| Yes | 0.045–0.316 | 0.27 | 0.012 | 0.04 | p>0.05 | 7.24–10.25 | 8.81±0.76 | 1.33 | 0.09 | p>0.05 | -26.51– -20.07 | -22.45 | 1.44 | 0.02 | p>0.05 | |
| No | 0.045–0.291 | 0.27 | 0.030 | 7.74–10.84 | 8.91±0.64 | 1.35 | -26.51– -20.86 | -22.47 | 2.68 | |||||||
| DoI (mm) | ||||||||||||||||
| ≤ 10 mm | 0.104–0.312 | 0.27 | 0.011 | 0.03 | p>0.05 | 7.24–10.84 | 8.81±0.84 | 1.08 | 0.14 | p>0.05 | -25.76– -20.07 | -22.70 | 1.62 | 0.04 | p>0.05 | |
| > 10 mm | 0.045–0.316 | 0.27 | 0.010 | 7.74–9.86 | 8.88±0.60 | 1.17 | -26.51– -21.29 | -22.70 | 1.52 | |||||||
| Angioinvasion or Neuroinvasion | ||||||||||||||||
| Yes | 0.045–0.280 | 0.27 | 0.009 | 0.06 | p>0.05 | 7.90–10.22 | 8.92±0.56 | 1.38 | 0.18 | p>0.05 | -26.51– -20.07 | -22.26 | 1.15 | 4.03 | p<0.05 | |
| No | 0.045–0.316 | 0.27 | 0.034 | 7.24–10.84 | 8.80±0.81 | 1.27 | -26.51– -20.86 | -22.75 | 2.68 | |||||||
| ENE(+) (ipsilateral or contralateral) | ||||||||||||||||
| Yes | 0.214–0.316 | 0.28 | 0.018 | 0.08 | p>0.05 | 7.24–10.22 | 8.87±0.74 | 1.19 | 0.16 | p>0.05 | -23.92– -20.07 | -22.38 | 1.15 | 0.05 | p>0.05 | |
| No | 0.045–0.291 | 0.27 | 0.026 | 7.74–10.84 | 8.83±0.69 | 1.47 | -26.51– -20.86 | -22.71 | 2.68 | |||||||
| Keratodes | ||||||||||||||||
| Yes | 0.045–0.316 | 0.27 | 0.011 | 0.03 | p>0.05 | 7.24–10.22 | 8.84±0.68 | 1.27 | 0.07 | p>0.05 | -26.51– -20.07 | -22.44 | 2.16 | 0.06 | p>0.05 | |
| No | 0.104–0.291 | 0.27 | 0.150 | 7.50–10.84 | 8.89±0.93 | 2.12 | -24.69– -22.01 | -22.72 | 2.02 | |||||||
| Grade | ||||||||||||||||
| G1 | 0.104–0.312 | 0.27 | 0.168 | 0.05 | p>0.05 | 7.24–10.84 | 8.63±0.95 | 1.09 | 0.13 | p>0.05 | -24.68– -21.37 | -22.70 | 1.83 | 0.07 | p>0.05 | |
| G2 | 0.045–0.316 | 0.27 | 0.014 | 7.50–10.22 | 8.90±0.65 | 1.27 | -26.51– -20.07 | -22.41 | 2.48 | |||||||
| G3 | 0.045–0.278 | 0.27 | 0.229 | 8.55–9.66 | 8.89±0.62 | 1.06 | -26.51– -21.29 | -22.58 | 4.21 | |||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).